Literature DB >> 23553913

Elevated rho-kinase activity as a marker indicating atherosclerosis and inflammation burden in polyvascular disease patients with concomitant coronary and peripheral arterial disease.

Ming Dong1, Xin Jiang, James K Liao, Bryan P Yan.   

Abstract

BACKGROUND: Recent evidence suggests that Rho-kinase (ROCK) plays an important role in the pathogenesis of atherosclerosis and a marker of atherosclerotic burden. Polyvascular disease with concomitant peripheral arterial disease (PAD) and coronary artery disease (CAD) is common and associated with a worse prognosis. The aim of this study was to evaluate ROCK activity as a marker of polyvascular disease.
METHODS: We retrospectively analyzed patients undergoing coronary angiography at our institution between February 2009 and May 2009. Patients with only CAD (n = 40) defined by coronary artery stenosis of ≥50% by angiography, only PAD (n = 40) defined by an ankle brachial index (ABI) <0.9, and combined CAD/PAD (n = 40) were matched by age and sex to control patients (n = 40) without CAD or PAD. ROCK activity was determined by phosphorylation of the myosin binding subunit in leukocytes and then compared between each group. Multivariate analysis was used to determine independent predictors of polyvascular disease. Discriminative ability of elevated ROCK activity was assessed using receiver operator characteristics (ROC) curves.
RESULTS: Patients (age 68 ± 12 years, 79% male) with CAD, PAD, and CAD/PAD had a mean ABI of 1.08, 0.62, and 0.65, respectively, compared to 1.08 in the control group. There was an incremental increase in ROCK activity in patients with CAD (4.61 ± 2.11), PAD (4.27 ± 1.39), and CAD/PAD (5.96 ± 1.94) compared to control (2.40 ± 0.43) (all P < 0.05). ROCK activity (odds ratio: 4.53, 95% confidence interval: 1.26-6.30) was an independent predictor of polyvascular disease. The ROCK cutoff value of 4.85 had a sensitivity of 72.7% and a specificity of 65.7%, with an area under ROC curve of 0.71 for polyvascular disease.
CONCLUSIONS: Patients with concomitant peripheral and coronary arterial disease are associated with increased Rho-kinase activity. Rho-kinase activity may be a potential marker of atherosclerotic burden for patients with polyvascular disease.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23553913      PMCID: PMC3807086          DOI: 10.1002/clc.22118

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  23 in total

1.  A method for measuring Rho kinase activity in tissues and cells.

Authors:  Ping-Yen Liu; James K Liao
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

2.  Enhanced Rho-kinase activity in circulating neutrophils of patients with vasospastic angina: a possible biomarker for diagnosis and disease activity assessment.

Authors:  Yoku Kikuchi; Satoshi Yasuda; Kentaro Aizawa; Ryuji Tsuburaya; Yoshitaka Ito; Morihiko Takeda; Masaharu Nakayama; Kenta Ito; Jun Takahashi; Hiroaki Shimokawa
Journal:  J Am Coll Cardiol       Date:  2011-09-13       Impact factor: 24.094

3.  Rho kinase contributes to basal vascular tone in humans: role of endothelium-derived nitric oxide.

Authors:  E Büssemaker; Frank Pistrosch; Sarah Förster; Kay Herbrig; Peter Gross; Jens Passauer; Ralf P Brandes
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-03-23       Impact factor: 4.733

Review 4.  Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.

Authors:  Ming Dong; Bryan P Yan; James K Liao; Yat-Yin Lam; Gabriel W K Yip; Cheuk-Man Yu
Journal:  Drug Discov Today       Date:  2010-06-25       Impact factor: 7.851

5.  Prevalence and prediction of previously unrecognized peripheral arterial disease in patients with coronary artery disease: the Peripheral Arterial Disease in Interventional Patients Study.

Authors:  Issam D Moussa; Michael R Jaff; Roxana Mehran; William Gray; George Dangas; Zoran Lazic; Jeffery W Moses
Journal:  Catheter Cardiovasc Interv       Date:  2009-05-01       Impact factor: 2.692

6.  A biomarker panel for peripheral arterial disease.

Authors:  Eric T Fung; Andrew M Wilson; Fujun Zhang; Nathan Harris; Kim A Edwards; Jeffrey W Olin; John P Cooke
Journal:  Vasc Med       Date:  2008-08       Impact factor: 3.239

7.  Increased leukocyte ROCK activity in patients after acute ischemic stroke.

Authors:  Steven K Feske; Farzaneh A Sorond; Galen V Henderson; Minoru Seto; Asako Hitomi; Koh Kawasaki; Yasuo Sasaki; Toshio Asano; James K Liao
Journal:  Brain Res       Date:  2008-12-25       Impact factor: 3.252

8.  Hypercoagulability markers in patients with peripheral arterial disease: association to ankle-brachial index.

Authors:  Ana Paula Lucas Mota; Maria Elizabeth Rennó de Castro Santos; Francisco das Chagas Lima e Silva; Natália Castro de Carvalho Schachnik; Marinez de Oliveira Sousa; Maria das Graças Carvalho
Journal:  Angiology       Date:  2008-11-17       Impact factor: 3.619

9.  Baseline distribution and correlation analysis of hsCRP in an insurance applicant population.

Authors:  Kenneth J Krause; David S Williams; Nancy White
Journal:  J Insur Med       Date:  2008

10.  Statins inhibit Rho kinase activity in patients with atherosclerosis.

Authors:  Anju Nohria; Adnan Prsic; Ping-Yen Liu; Ryuji Okamoto; Mark A Creager; Andrew Selwyn; James K Liao; Peter Ganz
Journal:  Atherosclerosis       Date:  2008-12-24       Impact factor: 5.162

View more
  3 in total

Review 1.  A review of the pathophysiology and potential biomarkers for peripheral artery disease.

Authors:  Smriti Murali Krishna; Joseph V Moxon; Jonathan Golledge
Journal:  Int J Mol Sci       Date:  2015-05-18       Impact factor: 5.923

2.  Data for increased Rho kinase activity in type 2 diabetic patients.

Authors:  Lei Liu; Lun Tan; Jinsheng Lai; Sheng Li; Dao Wen Wang
Journal:  Data Brief       Date:  2016-11-16

3.  Decreased thromboembolic stroke but not atherosclerosis or vascular remodelling in mice with ROCK2-deficient platelets.

Authors:  Nikola Sladojevic; Goo Taeg Oh; Hyung-Hwan Kim; Lea M Beaulieu; Hervé Falet; Karol Kaminski; Jane E Freedman; James K Liao
Journal:  Cardiovasc Res       Date:  2017-09-01       Impact factor: 10.787

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.